Navigation Links
Tutogen Medical, Inc. Reports First Quarter Fiscal 2008 Financial Results
Date:2/6/2008

ross margin of 61% in the same quarter of the previous year due to a less favorable product mix and yields and backorders of higher margin products. Operating expenses for the first quarter of fiscal year 2008 included $1.6 million in costs associated with the proposed merger. Operating expenses were also impacted by $227,000 resulting from the implementation of procedures relating to compliance with the Sarbanes Oxley Act of 2002. The Company is not expected to incur any additional material costs relating to Sarbanes-Oxley for the remaining quarters of fiscal year 2008. During the quarter, the Company incurred $445,000 in SFAS 123(R) stock option expense. For the three months ended December 31, 2007, the net loss totaled $1.3 million or $.07 basic loss per share and $.07 diluted loss per share. Excluding the $1.6 million in costs associated with the proposed merger, the Company would have reported net income of $343,000, or $0.02 per fully diluted share, compared to net income of $361,000, or $0.02 per fully diluted share, in the comparable quarter a year ago.

Guy L. Mayer, Chief Executive Officer of Tutogen Medical, said, "From an operating perspective, we are pleased with the continued double-digit growth in virtually all product and geographic segments. U.S. revenues grew 30%, led by continuing momentum in Surgical Specialties, with a 73% increase, and by a strong 27% increase in domestic dental product revenues."

"We also achieved outstanding growth internationally, with a 32% increase. We believe that our products have the potential to become market leaders internationally, and particularly in Europe. Going forward, as our distribution partners more fully embed our products in international markets, we believe strong and consistent future growth can be achieved."

Mr. Mayer commented on the proposed merger with Regeneration Technologies, Inc. "As the date approaches we very much look forward to the combination of the companies and the signi
'/>"/>

SOURCE Tutogen Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Tutogen Medical, Inc. to Present at the Roth Capital Partners 2007 New York Conference
2. Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products
3. Zimmer and Tutogen Announce Agreement for International Distribution of Biological Products
4. Tutogen Medical, Inc. to Report Fourth Quarter and Fiscal Year 2007 Financial Results
5. Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results
6. Nonin Medical, Inc. Receives Frost & Sullivans 2007 Award for Product Differentiation Innovation
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. QMed, Inc. Reports July Medicare SNP Enrollments
9. Phlo Affiliate Reports Expanded Coverage to Oregon Border
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... Asymmetrex, LLC ... in evaluating the full range of capabilities of its unique cache of technologies ... perform the day-to-day renewal and repair of normal tissues and organs. This property ...
(Date:7/28/2015)... A n ... rapidly developing and commercialising innovative medicines to transform patient quality ... Highly experienced management team; blue chip ... Mereo BioPharma Group Ltd ("Mereo"), a recently-formed speciality biopharmaceutical company, ... £76.5m), gross, from blue chip institutional investors and simultaneously acquired ...
(Date:7/28/2015)... ... July 29, 2015 , ... The new Xsample 530 sample changer for vials ... wide range of liquid viscosities – from less than 12,000 mPas (internal air) up to ... , What immediately catches the eye about Xsample 530 is its removable magazine, which ...
(Date:7/28/2015)... YORK , July 28, 2015 People ... by hearing aids achieved significant and sometimes profound improvements ... cochlear implant devices, according to a new multicenter study ... In the study, described online ahead of print in ... medical centers and private clinics in the ...
Breaking Biology Technology:Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11New Moves in Automatic Sample Handling: Introducing Xsample 530 2Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 2Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 3
... be Delivered by November 2007, BARCELONA, Spain, ... II trial includes 332 patients,with Overactive Bladder (OAB) ... 11,countries (US, Germany, Spain, The Netherlands, Czech Republic, ... The company,expects to report the results of this ...
... Calif., Oct. 9 VNUS(R) Medical,Technologies, Inc. (Nasdaq: ... minimally invasive treatment of peripheral vascular disease,announced today that ... third,quarter ended September 30, 2007, before market opens on ... quarterly teleconference at 5:30 a.m. PT,/ 8:30 a.m. ET ...
... Bavarian Nordic,the Danish-based international biopharmaceutical company, has ... Services (HHS) to,invoice an advance payment of $50 ... manufacture and deliver 20 million doses of the,company,s, ... payment because Bavarian Nordic fulfilled a,number of significant ...
Cached Biology Technology:SALVAT has Completed Patient Enrollment in a Dose Finding Phase II Trial of SVT-40776 for the Treatment of Overactive Bladder 2VNUS Medical Technologies to Report Third-Quarter 2007 Results and Webcast Teleconference on October 29 2Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones 2Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones 3
(Date:7/27/2015)... LOS ANGELES , July 27, 2015 /PRNewswire/ ... providing evidence- and experience-based clinical improvement solutions, today ... coordination solution is now available on Android smartphones ... at inpatient and post-care organizations can use ZynxCarebook ... the same patient,s condition, streamline care transitions to ...
(Date:7/21/2015)... Connecticut , July 21, 2015  NXT-ID, ... "Company"), a biometric authentication company focused on the ... Wocket® smart wallet, announces that it has filed ... System and Method. This invention ... not only authorizes an account, but also the ...
(Date:7/13/2015)... Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD ... convenient and secure method to make payments.  With ... methods, introduced with its groundbreaking voice-direct payment patent ...
Breaking Biology News(10 mins):Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4
... 130 osteoporosis patient society representatives gathered in Valencia, Spain ... Conference of Osteoporosis Patient Societies. Osteoporosis is ... fractures in as many as one in two women ... 50 worldwide. International Osteoporosis Foundation (IOF) CEO Patrice ...
... the Chair of the Department of Zoology and Neurobiology at ... a week after birth, they eliminated a particular protein in ... cells. "It,s the first time that we have gained an ... "We can now start conducting research to develop new therapeutic ...
... a subtropical, deciduous fruit tree grown in most Mediterranean-type ... oldest cultivated fruit species on earth, global expansion of ... base pertaining to production practices and the limited number ... were established in the Mediterranean-type climate of Western Cape ...
Cached Biology News:Important role for the cerebellum 2Optimizing yield and fruit size of figs 2
... BD FACSVantageTM SE flow cytometry system is ... laboratory. For over 25 years, BD cell ... are found in leading university, pharmaceutical, and ... To meet the research demands of today, ...
Reacti-Bind DNA Coating Solution...
... allows real-time observations of cell cultures under ... 64 different strain parameters in addition to ... silicon strain chamber used by the ST-195 ... microscopy. ST-195 can be used with Nikon, ...
... and regulate cell stretching or compression of ... stage. Computer controlled so you can precisely ... strain to produce 64 unique strain parameters. ... the ST-150. Both models are compatible with ...
Biology Products: